WuXi AppTec (603259)
WuXi AppTec (603259)
Overview
PharmaMing Kangde (stock code 603259.SH/2359.HK) is a leading global contract research, development and production (CRDMO) company with operations in Asia, Europe and North America, serving more than 6,000 partners in more than 30 countries around the world. Its WuXi tides platform focuses on one-stop CRDMO services for APIs and formulations of oligonucleotides, polypeptides and related chemically coupled drugs, covering the entire lifecycle from drug discovery to commercialization. The polypeptide manufacturing base is located in Changzhou and Taixing, Jiangsu: The Changzhou base has more than 20 polypeptide production lines, and the total volume of solid phase polypeptide synthesis (SPPs) reactors after integration with Taixing has exceeded 41,000 liters (32,000 liters after expansion in 2024, 100,000 liters at the end of 2025, and planned to expand to 130,000 liters). In 2023, it supports about 50 preclinical to commercial polypeptide projects, delivering more than 15 tons of polypeptide APIs and intermediates. The Changzhou base has passed regulatory inspections by the FDA in the United States, NMPA in China, PMDA in Japan, MFDs in South Korea, and ANVISA in Brazil many times.
Notes
WuXi AppTec (603259)。